Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Postgraduate Medicine
|
July 13, 2021
A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment
Elliott J Brea, Bruce C Tiu, Jean M Connors
Health Security
|
July 25, 2017
On Defining Global Catastrophic Biological Risks
Megan J Palmer, Bruce C Tiu, Amy S Weissenbach, et al.
Journal of the National Cancer Institute
|
February 21, 2022
Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy
Kimberly Tang, Bruce C Tiu, Guihong Wan, et al.
The Oncologist
|
February 23, 2023
Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
Bruce C Tiu, Ian A Strohbehn, Sophia Zhao, et al.
Journal of the American Academy of Dermatology
|
February 11, 2023
Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events: A population-level cohort study
Bonnie W Leung, Michael Ryan Collier, Bruce C Tiu, et al.
Oncotarget
|
February 4, 2016
Small molecule screen for inhibitors of expression from canonical CREB response element-containing promoters
Bryan Mitton, Katie Hsu, Ritika Dutta, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2022
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
Bruce C Tiu, Leyre Zubiri, James Iheke, et al.
JAMA Dermatology
|
January 12, 2022
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy
Kimberly Tang, Jayhyun Seo, Bruce C Tiu, et al.
Thrombosis Research
|
June 11, 2023
Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study
Behnood Bikdeli, Candrika D Khairani, Darsiya Krishnathasan, et al.
Journal of the American Heart Association
|
December 11, 2025
Adjudicated Cardiovascular Events in Patients With COVID-19: Association With Vaccination Status and Changes over Time
Behnood Bikdeli, Darsiya Krishnathasan, Antoine Bejjani, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Postgraduate Medicine
|
July 13, 2021
A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment
Elliott J Brea, Bruce C Tiu, Jean M Connors
Health Security
|
July 25, 2017
On Defining Global Catastrophic Biological Risks
Megan J Palmer, Bruce C Tiu, Amy S Weissenbach, et al.
Journal of the National Cancer Institute
|
February 21, 2022
Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy
Kimberly Tang, Bruce C Tiu, Guihong Wan, et al.
The Oncologist
|
February 23, 2023
Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
Bruce C Tiu, Ian A Strohbehn, Sophia Zhao, et al.
Journal of the American Academy of Dermatology
|
February 11, 2023
Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events: A population-level cohort study
Bonnie W Leung, Michael Ryan Collier, Bruce C Tiu, et al.
Oncotarget
|
February 4, 2016
Small molecule screen for inhibitors of expression from canonical CREB response element-containing promoters
Bryan Mitton, Katie Hsu, Ritika Dutta, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2022
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
Bruce C Tiu, Leyre Zubiri, James Iheke, et al.
JAMA Dermatology
|
January 12, 2022
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy
Kimberly Tang, Jayhyun Seo, Bruce C Tiu, et al.
Thrombosis Research
|
June 11, 2023
Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study
Behnood Bikdeli, Candrika D Khairani, Darsiya Krishnathasan, et al.
Journal of the American Heart Association
|
December 11, 2025
Adjudicated Cardiovascular Events in Patients With COVID-19: Association With Vaccination Status and Changes over Time
Behnood Bikdeli, Darsiya Krishnathasan, Antoine Bejjani, et al.
Page
of 2